In This Article:
Potential Radiopharm Theranostics Limited (ASX:RAD) shareholders may wish to note that the Non-Executive Director, Ian Turner, recently bought AU$150k worth of stock, paying AU$0.04 for each share. We reckon that's a good sign, especially since the purchase boosted their holding by 430%.
See our latest analysis for Radiopharm Theranostics
The Last 12 Months Of Insider Transactions At Radiopharm Theranostics
Notably, that recent purchase by Ian Turner is the biggest insider purchase of Radiopharm Theranostics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of AU$0.032. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
Radiopharm Theranostics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Radiopharm Theranostics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Insider Ownership
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 9.4% of Radiopharm Theranostics shares, worth about AU$6.6m, according to our data. However, it's possible that insiders might have an indirect interest through a more complex structure. We do generally prefer see higher levels of insider ownership.
So What Does This Data Suggest About Radiopharm Theranostics Insiders?
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Radiopharm Theranostics insiders are reasonably well aligned, and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Radiopharm Theranostics. Case in point: We've spotted 4 warning signs for Radiopharm Theranostics you should be aware of, and 2 of these don't sit too well with us.